Isolated and combined action of tamoxifen and metformin in wild-type, tamoxifen-resistant, and estrogen-deprived MCF-7 cells (Q39671678)

13 September 2017

Isolated and combined action of tamoxifen and metformin in wild-type, tamoxifen-resistant, and estrogen-deprived MCF-7 cells (English)

1 reference

13 September 2017

1 reference

1 reference

Lev M Berstein

1

1 reference

13 September 2017

Wei Yue

series ordinal

2

1 reference

13 September 2017

Ji-Ping Wang

series ordinal

3

1 reference

13 September 2017

Richard J Santen

series ordinal

4

1 reference

13 September 2017

language of work or name

English

0 references

publication date

4 August 2010

1 reference

Breast Cancer Research and Treatment

13 September 2017

1 reference

13 September 2017

128

1 reference

13 September 2017

1

1 reference

13 September 2017

109-117

1 reference

https://scigraph.springernature.com/pub.10.1007/s10549-010-1072-z

13 September 2017

0 references

cites work

Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1072-Z

Design, conduct, and analyses of Breast International Group (BIG) 1-98: a randomized, double-blind, phase-III study comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive, early breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1072-Z

Targeting of tamoxifen to enhance antitumour action for the treatment and prevention of breast cancer: the 'personalised' approach?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1072-Z

The effect of tamoxifen on the genital tract

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1072-Z

Biological determinants of endocrine resistance in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1072-Z

Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1072-Z

Tamoxifen resistance in breast cancer: elucidating mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1072-Z

Adaptive hypersensitivity to estradiol: potential mechanism for secondary hormonal responses in breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1072-Z

Long-term estradiol deprivation in breast cancer cells up-regulates growth factor signaling and enhances estrogen sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1072-Z

Decreased BRCA1 confers tamoxifen resistance in breast cancer cells by altering estrogen receptor-coregulator interactions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1072-Z

Targeting of cancer energy metabolism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1072-Z

Clinical usage of hypolipidemic and antidiabetic drugs in the prevention and treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1072-Z

New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1072-Z

Long-term metformin use is associated with decreased risk of breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1072-Z

Effect of metformin on life span and on the development of spontaneous mammary tumors in HER-2/neu transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1072-Z

Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1072-Z

Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1072-Z

Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1072-Z

Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1072-Z

Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1072-Z

Insulin-lowering effects of metformin in women with early breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1072-Z

Metformin in breast cancer: time for action

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1072-Z

Metformin, insulin, breast cancer and more...

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1072-Z

Is it time to test metformin in breast cancer clinical trials?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1072-Z

Subcellular localization of cyclic AMP-responsive element binding protein-regulated transcription coactivator 2 provides a link between obesity and breast cancer in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1072-Z

Mechanisms of acquired resistance to endocrine therapy in hormone-dependent breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1072-Z

New approaches to the understanding of tamoxifen action and resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1072-Z

Effects of metformin on mammalian target of rapamycin in a mouse model of endometrial hyperplasia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1072-Z

The LKB1-AMPK pathway: metabolism and growth control in tumour suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1072-Z

Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1072-Z

Estradiol stimulates Akt, AMP-activated protein kinase (AMPK) and TBC1D1/4, but not glucose uptake in rat soleus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1072-Z

LKB1 catalytic activity contributes to estrogen receptor alpha signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1072-Z

Metformin induces unique biological and molecular responses in triple negative breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1072-Z

Proautophagic drugs: a novel means to combat apoptosis-resistant cancers, with a special emphasis on glioblastomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1072-Z

Metformin inhibits aromatase via an extracellular signal-regulated kinase-mediated pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1072-Z

Modulation of aromatase expression by BRCA1: a possible link to tissue-specific tumor suppression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1072-Z

BRCA1 and BRCA2 as molecular targets for phytochemicals indole-3-carbinol and genistein in breast and prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1072-Z

Effect of fenretinide and low-dose tamoxifen on insulin sensitivity in premenopausal women at high risk for breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1072-Z

Metformin: a therapeutic opportunity in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1072-Z

Utility of metformin in breast cancer treatment, is neoangiogenesis a risk factor?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1072-Z

Metformin is a potent inhibitor of endometrial cancer cell proliferation--implications for a novel treatment strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1072-Z

Measurement of metformin concentration in erythrocytes: clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1072-Z

Tamoxifen and metabolite concentrations in serum and breast cancer tissue during three dose regimens in a randomized preoperative trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1072-Z

Therapeutic metformin/AMPK activation promotes the angiogenic phenotype in the ERalpha negative MDA-MB-435 breast cancer model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1072-Z

Therapeutic metformin/AMPK activation promotes the angiogenic phenotype in the ERalpha negative MDA-MB-435 breast cancer model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1072-Z

10.1007/S10549-010-1072-Z

21 January 2018

Identifiers

DOI

1 reference

13 September 2017

1 reference